High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia

QJM: An International Journal of Medicine

Volumn 91, Issue 4, 1998, Pages 291-294

  Wierzbicki, A S ^a   Lumb, P J ^a   Semra, Y K ^a   Crook, M A ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; COLESTYRAMINE; CREATINE KINASE; FENOFIBRATE; RESIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG MEGADOSE; ENZYME ACTIVITY; HUMAN; HYPERCHOLESTEROLEMIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MUSCLE FUNCTION; MYALGIA; PRIORITY JOURNAL; RASH;

EID: 0031949584     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/91.4.291     Document Type: Article

References (11)

1. Anonymous. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. Br Med J 1991; 303:893-6.
2. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
3. Shepherd J, Cobbe SM, Ford I, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-9.
4. Wierzbicki AS, Lumb PJ, Cheung J, Crook MA. Experience with simvastatin-fenofibrate combination therapy compared to simvastatin-cholestyramine therapy for familial hypercholesterolaemia. Q J Med 1997; 90:631-4.
5. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 21-60% in patients with primary hypercholesterolaemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arteriosclerosis Thromb Vasc Biol 1995; 15:678-82.
6. 100 in plasma. J Clin Path 1994; 47:176-8.
7. Watts GF, Mazurkiewicz JC, Tonge K, Nelson V, Warburton FG, Slavin BM. Lipoprotein (a) as a determinant of the severity of angiographically defined carotid atherosclerosis. Q J Med 1995; 88:321-6.
8. Black DM. Atorvastatin: a step ahead for HMG-CoA reductase inhibitors. Atherosclerosis X 1995; 307-10.
9. Ooi TC, Heinonen T, Alaupovic P, et al. Efficacy and safety of a new hydroxy-methyl-glutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidaemia: comparison with fenofibrate. Arteriosclerosis Thromb Vasc Biol 1997; 17:1793-9.
10. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor atorvastatin in patients with hypertriglyceridaemia. JAMA 1996; 275:128-33.
11. Forster LF, Stewart G, Bedford DK, Stewart JP, Caslake M, Packard CJ, Shepherd J, Black DM. Stable isotope turnover studies of apolipoprotein B in combined hyperlipidaemia before and after treatment with atorvastatin, a new HMG-CoA reductase inhibitor. Arteriosclerosis Thromb Vasc Biol 1996; 16(suppl. 1): 41 (Abstract 06356).